Favipiravir, Drugs Monitor

(27 May 2021) Favipiravir- FPV early had an impact on PCR negativity

May 31, 2021

Benefits of treatment with favipiravir in hospitalized patients for COVID-19: a retrospective observational case-control study https://doi.org/10.1186/s12985-021-01577-1 A retrospective observational case-controlled cohort study was performed between March and September 2020, including adults with COVID-19 in a single-center in Turkey. We categorized… Continue reading "(27 May 2021) Favipiravir- FPV early had an impact on PCR negativity"

(01 May 2021) Favipiravir- found to be superior in shortening the duration of viral shedding

May 24, 2021

Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: A multicenter, open-label, randomized trial https://doi.org/10.1016/j.intimp.2021.107702 NCT04333589- Between March 27 and May 9, 2020, 55 patients underwent randomization; 36 were assigned to the favipiravir group and 19… Continue reading "(01 May 2021) Favipiravir- found to be superior in shortening the duration of viral shedding"

(24 Apr 2021) Favipiravir- was associated with accelerated discharge rate

April 30, 2021

Effectiveness and safety of favipiravir compared to supportive care in moderately to critically ill COVID-19 patients: A retrospective study with propensity score matching sensitivity analysis https://doi.org/10.1080/03007995.2021.1920900 Overall, median time to discharge was 10 days (95%CI =9-10) in the favipiravir arm… Continue reading "(24 Apr 2021) Favipiravir- was associated with accelerated discharge rate"

(02 Apr 2021) Favipiravir- safe effective alternative for hydroxychloroquine in mild or moderate COVID-19 infected patients

April 29, 2021

Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial https://doi.org/10.1038/s41598-021-85227-0 NCT04349241- t was randomized-controlled open-label interventional phase 3 clinical trial. 100 patients were recruited from 18th April till 18th May. 50 patients received favipiravir… Continue reading "(02 Apr 2021) Favipiravir- safe effective alternative for hydroxychloroquine in mild or moderate COVID-19 infected patients"

(19 Mar 2021) Favipiravir- did not shorten time to clinical recovery and length of hospital stay

April 7, 2021

Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia https://doi.org/10.1016/j.intimp.2021.107522 IRCT20200318046812N1- 380 patients were randomly allocated into Favipiravir (193) and Lopinavir/Ritonavir (187) groups in 13 centers. The number of deaths, intubations, and ICU admissions were not significantly different… Continue reading "(19 Mar 2021) Favipiravir- did not shorten time to clinical recovery and length of hospital stay"

(18 Mar 2021) Favipiravir- was more effective than LPV/RTV in reducing mortality

April 7, 2021

The Comparison of Lopinavir/Ritonavir Combination and Favipiravir In COVID-19 Treatment https://doi.org/10.3906/sag-2012-189 Of the 204 patients with COVID-19 pneumonia, 59 (28.9%), 131 (64.2%), and 14 were administered LPV/RTV, favipiravir, and favipiravir with LPV/RTV, respectively. No difference was found in age, sex,… Continue reading "(18 Mar 2021) Favipiravir- was more effective than LPV/RTV in reducing mortality"

(26 Jan 2021) Favipiravir- decreases the hospital stay and the need for mechanical ventilation

January 28, 2021

Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study https://doi.org/10.1007/s00705-021-04956-9 NCT04351295-This was a multicenter randomized controlled study including 96 patients with COVID- 19 who were randomly assigned into a chloroquine (CQ) group and a favipiravir group. None of the… Continue reading "(26 Jan 2021) Favipiravir- decreases the hospital stay and the need for mechanical ventilation"

(01 Jan 2021) Tocilizumab- TCZ with or without favipiravir can effectively improved the pulmonary inflammation of COVID-19 patients

January 2, 2021

Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size https://doi.org/10.1016/j.biopha.2020.110825 This was a multicenter trial (ChiCTR2000030894 and NCT04310228) in adults with COVID-19. Patients were randomly assigned (3:1:1) to a 14-day combination of… Continue reading "(01 Jan 2021) Tocilizumab- TCZ with or without favipiravir can effectively improved the pulmonary inflammation of COVID-19 patients"

(09 Dec 2020) Favipiravir- did not seem to affect disease progression

December 14, 2020

Role of favipiravir in the treatment of adult patients with moderate to severe COVID-19: a single-center, prospective, observational, sequential cohort study from Hungary https://www.medrxiv.org/content/10.1101/2020.11.26.20238014v1 In all, 75 patients were included per cohort. In the FVP cohort, chronic heart disease (36/75,… Continue reading "(09 Dec 2020) Favipiravir- did not seem to affect disease progression"

(26 Nov 2020) Favipiravir- associated with significant clinical and laboratory improvements

November 27, 2020

Treatment of SARS-cov-2 pneumonia with favipiravir: Early results from the Ege University cohort, Turkey https://doi.org/10.3906/sag-2008-33 This retrospective descriptive study included patients diagnosed with COVID-19 who presented with or developed severe pneumonia. Forty patients who completed a full course (at least… Continue reading "(26 Nov 2020) Favipiravir- associated with significant clinical and laboratory improvements"

Tag: Favipiravir